Khaled Abduljalil

List of Publications by Year in Descending Order

39 papers	1,106 citations	17 h-index	33 g-index
42 ext. papers	1,333 ext. citations	4.5 avg, IF	4.7 L-index

#	Paper	IF	Citations
39	Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.. *Clinical Pharmacokinetics*, **2022**, 1	6.2	2
38	.. *Drug Metabolism and Disposition*, **2022**,	4	4
37	Quantification of Fetal Renal Function Using Fetal Urine Production Rate and Its Reflection on the Amniotic and Fetal Creatinine Levels During Pregnancy.. *Frontiers in Pediatrics*, **2022**, 10, 841495	3.4	3
36	Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section. *Pharmaceutics*, **2022**, 14, 1162	6.4	0
35	AuthorsRReply to Vller et al: "Comment on: Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II". *Clinical Pharmacokinetics*, **2021**, 60, 681-683	6.2	0
34	Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect. *Journal of Clinical Pharmacology*, **2021**, 61, 1356-1365	2.9	2
33	Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 10, 878-889	4.5	5
32	Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial. *British Journal of Clinical Pharmacology*, **2021**, 87, 1378-1389	3.8	6
31	Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Cardiac Output and Its Distribution to Different Organs during Development. *Clinical Pharmacokinetics*, **2021**, 60, 741-757	6.2	4
30	Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. *Journal of Pharmacokinetics and Pharmacodynamics*, **2020**, 47, 319-340	2.7	16
29	Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. *AAPS Journal*, **2020**, 22, 76	3.7	12
28	Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy. *Current Drug Metabolism*, **2020**, 21, 722-741	3.5	
27	Fetal Physiologically Based Pharmacokinetic Models: Systems Information on Fetal Blood Components and Binding Proteins. *Clinical Pharmacokinetics*, **2020**, 59, 629-642	6.2	9
26	Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 1352-1361	6.1	15
25	Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. *Journal of Pharmacokinetics and Pharmacodynamics*, **2020**, 47, 361-383	2.7	11
24	A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building. *Clinical Pharmacokinetics*, **2020**, 59, 485-500	6.2	18
23	Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population. *Clinical Pharmacokinetics*, **2020**, 59, 501-518	6.2	22

22	Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs. *Clinical Pharmacokinetics*, **2019**, 58, 235-262	6.2	25
21	Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 103-110	4.5	37
20	Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition. *Clinical Pharmacokinetics*, **2018**, 57, 1149-1171	6.2	24
19	Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. *Biopharmaceutics and Drug Disposition*, **2018**, 39, 125-134	1.7	8
18	More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. *Journal of Clinical Pharmacology*, **2016**, 56 Suppl 7, S132-42	2.9	16
17	A Tutorial on Pharmacodynamic Scripting Facility in Simcyp. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 455-65	4.5	7
16	Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio. *Drug Metabolism and Disposition*, **2016**, 44, 1099-102	4	21
15	Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 245-57	1.7	87
14	A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. *Clinical Pharmacokinetics*, **2014**, 53, 625-36	6.2	80
13	Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin. *CPT: Pharmacometrics and Systems Pharmacology*, **2014**, 3, e124	4.5	56
12	Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. *Frontiers in Pharmacology*, **2014**, 5, 258	5.6	32
11	Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. *Drug Metabolism and Disposition*, **2014**, 42, 1478-84	4	71
10	Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. *AAPS Journal*, **2014**, 16, 568-76	3.7	55
9	Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. *Clinical Pharmacokinetics*, **2013**, 52, 359-71	6.2	4
8	A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. *British Journal of Clinical Pharmacology*, **2012**, 74, 873-85	3.8	80
7	Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. *Clinical Pharmacokinetics*, **2012**, 51, 365-96	6.2	210
6	Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. *Current Drug Metabolism*, **2012**, 13, 695-720	3.5	35
5	Physiologically-Based Pharmacokinetics **2011**, 361-386		

4	Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. *Clinical Pharmacology and Therapeutics*, **2010**, 88, 643-51	6.1	43
3	Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 207-12	5.9	58
2	Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 2892-901	5.9	15
1	Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops. *European Journal of Clinical Pharmacology*, **2008**, 64, 521-9	2.8	6